Leveraging Alzheon experience

A leader in Alzheimer’s science & therapeutics

Martin Tolar, MD, PhD

  • Founder of Tolion Health, Inc.
  • Founder of INDRC institute
    • AI in neurodegenerative disorders
  • Founder, President & CEO of Alzheon, Inc.
  • CEO of NormOxys, Inc. & Knome, Inc.

Alzheon

  • Discovered Alzheimer’s disease toxin
    • Leading investigational treatment ALZ-801

Tolion

  • Brain Coach App – synergistic product with ALZ-801
  • Collaboration with Alzheon channels & payers

Alzheimer’s dementia is preceded by a long silent pre-symptomatic phase

Initial target groups

135.5 million people aged 40 – 65 at risk for dementia globally*

People with high-risk APOE4 genotype

People with predispositions & family history of dementia

Worried well

People at risk for dementia*

  • US – 15.7 million
  • Europe & Canada – 28.6 million
  • Asia, Australia, South America – 91.2 million
*alzint.org

Tackling the emerging dementia crisis

Initial focus on brain health enables performance & longevity guidance

Healthy BrainDementia Brain

Over 57M
people worldwide have dementia*

By 2050
this number is expected to more than double**

Over 47%
of dementia cases are preventable***

*who.int; **alzint.org; ***Livingstone (2024) Lancet